Endometriosis: First combination pill for treating symptoms to be rolled out in NHS

Elisabeth Mahase, Mahase E
BMJ (Clinical research ed.) · 2025 · vol. 388 , pp. r520 · doi:10.1136/bmj.r520 · PMID:40081845 · W4408397336
article OA: closed CC0
Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-07-21 ⓘ

The NHS will roll out a new combination pill for treating endometriosis symptoms, marking the first such medication approved for public healthcare provision.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-18 · read from full text ⓘ

This news report details the National Institute for Health and Care Excellence’s final draft guidance recommending relugolix combination therapy, a daily pill containing relugolix, oestradiol, and norethisterone, for symptom management. The treatment is expected to become available on the NHS in England, potentially benefiting approximately 1000 women annually who suffer from endometriosis. This development marks the first time this specific combination medication has been rolled out through the public healthcare system for this indication. This paper is centrally about endometriosis — specifically the introduction of a new pharmacological treatment option for symptom management within the NHS.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Full text 913 characters · extracted from oa-doi-fallback · click to expand
News Endometriosis: First combination pill for treating symptoms to be rolled out in NHS BMJ 2025; 388 doi: https://doi.org/10.1136/bmj.r520 (Published 13 March 2025) Cite this as: BMJ 2025;388:r520- Elisabeth Mahase - The BMJ A daily pill to treat the symptoms of endometriosis will soon be made available on the NHS, in a move that could benefit 1000 women a year in England.1 The National Institute for Health and Care Excellence’s final draft guidance has recommended the drug—a combination of relugolix, oestradiol, and norethisterone, known as relugolix combination therapy—as a treatment option … Log in Log in using your username and password Log in through your institution Subscribe from £184 * Subscribe and get access to all BMJ articles, and much more. * For online subscription Access this article for 1 day for: £50 / $60/ €56 (excludes VAT) You can download a PDF version for your personal record.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2025) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-08-26T06:08:41.316361+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-08-26T06:05:43.449365+00:00
License: CC0 · commercial use OK